ReviewAging2020
Clinical challenges in cancer patients with COVID-19: Aging, immunosuppression, and comorbidities.
Review in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pooled it
- Sex-based differences in mortality among a large cohort of hospitalized patients with RT-PCR-confirmed SARS-CoV-2 infection at five different pandemic waves in Northern Iran.Scientific reports · 2025Article
- N-acetylcysteine (NAC) supplementation improves dyspnea and may normalize von Willebrand plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID.Gynecologic oncology reports · 2025Article
- Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID.Gynecologic oncology reports · 2024Article
- Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID.Gynecologic oncology reports · 2023Article
- The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023Review
- Article
- Article
- Active cancer as the main predictor of mortality for COVID-19 in oncology patients in a specialized center.Pathology oncology research : POR · 2023Article
- Influenza Vaccine and COVID-19 Pandemic: Could This Vaccine Help Limit the Potential Adverse Consequences of SARS-CoV-2?Iranian journal of pharmaceutical research : IJPR · 2022Article
- Correlation between Type I Interferon Associated Factors and COVID-19 Severity.International journal of molecular sciences · 2022Review
- Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy.World journal of clinical oncology · 2022Article
- The Impact of SARS-CoV-2 Pandemic on Patients with Malignant Melanoma at a Romanian Academic Center: A Four-Year Retrospective Analysis.International journal of environmental research and public health · 2022Article
- SARS-CoV2 Infection and Comorbidities, Role in Oncogenesis.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant.Journal of medical virology · 2022Review
- Challenges posed by COVID-19 in cancer patients: A narrative review.Cancer medicine · 2022Review
- Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin.Pharmaceuticals (Basel, Switzerland) · 2021Article
- The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.Frontiers in oncology · 2021Review
- Impact of PEG-GCSF in Breast Cancer Patients Undergoing Chemotherapy During the COVID-19 Pandemic: Single Center Experience and Literature Review.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 caused by severe acute respiratory syndrome coronavirus 2 has developed into a global pandemic. COVID-19 poses a huge threat to health care, and the shortage of medical resources caused by COVID-19 brought serious secondary disasters to elderly cancer patients who are particularly dependent on medical resources. The clinical challenges of cancer management, including aging, immunosuppression, and comorbidities, make cancer patients more vulnerable to COVID-19 with different clinical manifestations, disease severity, and outcomes. The review comprehensively analyzed the characteristics of the cancer patients under the pandemic and concluded that cancer patients were more susceptible to COVID-19, and also concluded that they were more likely to develop poor outcomes and the severe form of the disease. Three basic management strategies have been proposed to protect susceptible elderly cancer patients, find reliable indicators to monitor the course of disease, and implement effective prevention measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.